KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Neogenomics (NEO) over the last 13 years, with Q3 2025 value amounting to $7.1 million.

  • Neogenomics' Asset Writedowns and Impairment changed N/A to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 1868896.55%. This contributed to the annual value of $450000.0 for FY2024, which is 7357.6% down from last year.
  • Neogenomics' Asset Writedowns and Impairment amounted to $7.1 million in Q3 2025.
  • Neogenomics' Asset Writedowns and Impairment's 5-year high stood at $20.0 million during Q2 2025, with a 5-year trough of $43000.0 in Q3 2023.
  • In the last 4 years, Neogenomics' Asset Writedowns and Impairment had a median value of $727500.0 in 2022 and averaged $3.7 million.
  • Data for Neogenomics' Asset Writedowns and Impairment shows a peak YoY increase of 8429.04% (in 2024) and a maximum YoY decrease of 8429.04% (in 2024) over the last 5 years.
  • Over the past 4 years, Neogenomics' Asset Writedowns and Impairment (Quarter) stood at $718000.0 in 2022, then crashed by 94.01% to $43000.0 in 2023, then soared by 172.09% to $117000.0 in 2024, then soared by 5956.41% to $7.1 million in 2025.
  • Its Asset Writedowns and Impairment was $7.1 million in Q3 2025, compared to $20.0 million in Q2 2025 and $117000.0 in Q4 2024.